Red flags in the GLP-1 vendor space — counterfeit semaglutide and underdosed vials

The GLP-1 peptide market has the worst counterfeit problem of any peptide class right now. The combination of high mainstream demand, high price point, and complex synthesis has created the worst possible economic conditions for product integrity. This thread covers the specific scam patterns that show up in this category and what to look for to avoid them.

Why this category is particularly affected.
Three factors converge. First, the mainstream attention from Wegovy and Mounjaro has created demand far beyond what legitimate research-grade manufacturing can supply. Second, the price point is high enough that counterfeit operations have meaningful margin even when selling at half the legitimate market rate. Third, the molecules themselves are large and structurally complex, which means counterfeits can be made from cheaper related peptides or partial synthesis byproducts and still pass casual inspection.

Pattern 1: The wrong-peptide counterfeit.
What the vial says: semaglutide. What is actually in the vial: liraglutide, exenatide, or another GLP-1 agonist that is cheaper to synthesize. The buyer experiences "GLP-1 effects" and assumes the product is legitimate. Detection requires mass spectrometry — HPLC alone will not catch it because the impurity profile of cheaper GLP-1 agonists looks "normal" on HPLC unless someone is specifically looking for the wrong molecular weight.

How to protect against it: demand mass spec on the COA. The observed molecular weight must match the theoretical weight for the specific compound. Semaglutide is 4113.58 Da. Tirzepatide is 4813.5 Da. If the COA does not include mass spec or shows a value that does not match, the product is suspect regardless of what HPLC purity shows.

Pattern 2: The underdosed vial.
What the vial says: 5mg of semaglutide. What is actually in the vial: 2-3mg of semaglutide. The product itself may be legitimate and pure — there is just less of it than labeled. This is arguably the most common quality issue in this category and the hardest to detect from documentation alone.

How to protect against it: ask whether the vendor offers quantitative content testing (not just purity percentage). Track subjective response carefully across vendors — if the same labeled dose from a different vendor produces noticeably stronger effects, the cheaper vendor is likely underdosed. Comparing experiences across vendors in community discussion threads is one of the best ways to catch this.

Pattern 3: The fake COA from a real lab.
A vendor obtains one legitimate COA from a real third-party lab. They then attach that COA to many subsequent batches that were never tested. When buyers try to verify by checking the lab name, they confirm the lab is real and stop investigating.

How to protect against it: contact the lab directly with the report number from the COA. Most accredited labs have a verification process — they will confirm whether they generated that specific report and whether it covers the batch number on the vial. If the lab cannot confirm the report or the batch number does not match what they tested, the COA is being recycled.

Pattern 4: The dropship "vendor" with no inventory.
A "domestic" vendor takes the order, then forwards it to a Chinese manufacturer for direct shipping. They have no inventory, no quality control, and no ability to verify what was actually shipped. When problems arise, they cannot resolve them because they never touched the product.

How to detect it: tracking that shows direct China-to-buyer shipping rather than domestic-to-buyer. Shipping times that do not match the claimed origin. Vendor that cannot answer specific questions about who synthesizes the product or where it is stored before shipping.

Pattern 5: The "pharmacy compounded" misrepresentation.
With the FDA reclassification activity in 2026, some vendors are claiming "pharmacy compounded" status to imply pharmaceutical-grade quality. Compounding pharmacies are specific licensed facilities with verifiable credentials. A vendor making this claim should be able to name the pharmacy and let the buyer verify the license. Most "pharmacy compounded" vendor claims in the research-grade space are misrepresentation.

Pattern 6: The price-too-low signal.
Synthesis cost for semaglutide and tirzepatide is real. Vendors selling significantly below market rate are economically improbable as legitimate operations. They are either operating at a loss (rare and short-lived) or the product is not what it claims to be (common). If a deal looks too good, model the unit economics — what would pure pharmaceutical-grade peptide cost to produce, and could the vendor possibly be selling at that price plus margin?

What to do if a suspect vendor was already used.
Document the COA received. If the vial arrived, get it tested independently if possible — third-party HPLC + mass spec testing exists for individuals, though it is expensive. Post specific findings on the platform with vendor name and batch number. Community-sourced quality data is one of the strongest defenses against this whole category of fraud.

If you are shopping for a vendor in this category and you are not sure how to evaluate the COA, post a redacted COA in the Quality and COA discussion thread and the community can help you read it.